Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Clinical Evidence Randomised controlled trial Bioquell UK undertook a 3 year randomised controlled clinical trial evaluating the efficacy of the BioxyQuell wound treatment system in primary care. The study was carried out in four General Practice Surgeries within Hampshire, UK and included long-term follow up of patients. The study evaluated a number of outcomes including microbiological reduction, pain, wound size reduction and wound healing. The results were published in the Journal of Wound Care and the abstract is provided below: Aqueous oxygen peroxide treatment of venous leg ulcers is associated with improved wound healing in a primary care based randomised, double-blind, placebo-controlled trial. Paul D. O’Halloran, FRCGP , Patricia K. Winter, RGN, Jonathan A. Otter, PhD , Nicholas M.T. Adams, BSc and John Chewins, MBS Objective:To evaluate a novel aqueous oxygen peroxide (AOP) wound therapy (BioxyQuell) in a multi-centre, primary care-based, randomised, double-blind, placebo-controlled, parallel-group trial, monitoring long term healing outcomes over 12 months. Method:Sixty-one patients with chronic, stable venous leg ulceration were treated with either AOP solution or sterile water placebo applied as a lavage over two weeks. The patient’s wounds were dressed weekly and assessed fortnightly over the following six weeks. Patients who completed the initial 8 week trial were invited into a 10 month follow-up trial. The primary endpoints of the study were wound healing at 8 weeks, 12 weeks, 6 months and 12 months and wound size reduction during the treatment phase. Secondary endpoints were reductions in wound bioburden and pain. Results:Patients treated with AOP were more likely to heal at 6 months (p=0.014) and 12 months (p=0.006), but not at 8 weeks (p=0.979) or 12 weeks (p=0.263). Patients treated with AOP had greater: (a) wound area reduction (p=0.015); (b) reductions in pain measured on a 100 point scale (p=0.001); and (c) wound bioburden reduction (p=0.005) during the treatment phase. Conclusion: The addition of AOP treatment provides substantial benefits to patients with chronic venous leg ulceration compared with current best practice. Published in Journal of Wound Care. April 2014. Vol 23: 4, P176-190. A copy of the full article is available at: http://www.journalofwoundcare.com/cgi-bin/go.pl/library/article.cgi?uid=104345;article=JWC_23_4_176_190
Agreed. Nice to see the dividend raise, they aren't exactly pulling up trees and it would be nice to get some more detailed backlog info, but this is a hold for me for now.
The results posted today are good, considering the tough years trading conditions. Dividend up 8%, Lets hope for a more positive move in the share price.
ideas why this is on the up?
Good to see the s/p fairly firm as compared to the general market and regaining all the fall into the 130s which I couldn't work out a logical reason for. Nice firm company which imo could well be a takeover target at some stage.
Thanks for that! Sounds like only a minor hiccup and sensible financial management. Still seems a solid hold with growing potential, will look to top up on any further weakness.
"We estimate that the aggregate revenue effect relating to these matters will be approximately £0.9m." Aside from this, the group has begun 2013 with a 12% increase in its opening order book of £17.2m (2011: £15.4m), with no significant change year-on-year in the defence order book. The Bio-decontamination division order book totalled £12.3m (72% of the total order book) and TRaC represented £4.9m (28%). In 2012, the group took orders worth £44.6m, up slightly from £44.4m in 2011, with an 'encouraging' performance from TRaC, where orders rose 18%, and revenues climbed 11%. Both orders and revenues hit a monthly record in December. Investec moved its target price from 137p to 130p and retained its hold rating on the stock.
Bioquell, a company which provides specialist bio-decontamination technologies to a range of markets, has admitted it suffered a 'slight shortfall' at the end of the year in orders expected for immediate shipment to Life Sciences customers based in continental Europe. As a result, full year revenue is now expected to be £41.0m, compared to £41.3m in 2011. The company also said it decided not to ship a number of orders before the year end from customers in the emerging markets because it was "unable to satisfy ourselves as to the robustness of the associated credit arrangements". The group added: "In addition, our defence invoicing in 2012 was held back at the very end of the year on one large defence contract due to slippage on matters unrelated to Bioquell's activities. Our business is highly operationally geared and such a reduction in revenues has a significant effect on our profitability.
any particular reason for this fall or is the market just too thin?
will finish the day at 1.60
av these tipped az a buy this morning........... page 77,a third of a page spread....... gla....
After the IMS today you'd think BQE would shoot north..!
1 mill trade ?..
2 December, 2011 BIOQUELL PLC Award of a GBP1.2 million development contract by General Dynamics as part of the new SV vehicle for the UK Ministry of Defence Bioquell PLC (LSE: BQE) ("Bioquell") - provider of specialist low temperature, residue-free bio-decontamination and filtration technologies to the healthcare, life sciences and defence sectors - announces that it has been awarded a GBP1.2 million development contract relating to the new reconnaissance vehicle being developed by General Dynamics for the UK Ministry of Defence. Background General Dynamics UK LLC, a subsidiary of the US General Dynamics Group, has been awarded a contract by the UK Ministry of Defence for the Specialist Vehicles Programme Demonstration, Manufacture and In-Service Support for the Reconnaissance Block 1 Vehicles and Common Base Platform (the "SV Programme"). Bioquell UK Limited, a subsidiary of Bioquell PLC, develops and manufactures, among other things, Chemical, Biological, Radiological and Nuclear ("CBRN") filtration systems as well as Environmental Control Systems ("ECS"). Contract award General Dynamics - Santa Barbara Sistemas, S.A., a Spanish subsidiary of the General Dynamics Group, has awarded Bioquell UK Limited a development contract worth approximately GBP1.2 million relating to ECS and CBRN systems for the demonstration phase of the SV Programme. Once this initial development contract has been fulfilled, it is expected that contracts relating to the manufacture and in-service phases will be awarded, with shipments expected to start in 2014 and expected to run for at least five years. Commenting on this contract award, Nick Adams, Group Chief Executive of Bioquell PLC, said: "We are extremely pleased to have been awarded this prestigious development contract relating to the British Army's new reconnaissance vehicle." - Ends - Enquiries: Bioquell PLC 01264 835 900 Nick Adams Group Chief Ex
Bioquell LONG-TERM BUY 02/09/2011 Miles Nolan Against low comparatives, bio-decontamination specialist Bioqeull (BQE) has quadrupled its pre-tax profits to £2m in the first half of 2011. Based around hydrogen peroxide vapour Bioquell has developed a patent-protected system which eradicates bacteria and viruses at room temperature. The system is used by biotechnology institutions as well as hospitals as they fight to eliminate potentially life threatening 'superbugs'. In the six months to June sales increased 11% to £20m, with the bio-decontamination arm hoisting its revenues 13% to £13.4m. Bioquell enjoyed higher demand for its kit in the UK and overseas, indeed it recently secured a $1m contract from China to use its products in research laboratories. As bio-pharmaceutical companies continue to seek sterile facilities Bioquell should be well placed to win new business, particularly in light of pressure to stop using the human carcinogen formaldehyde to sterilise facilities. Growth in the US healthcare market has proved sluggish, however interest from developing countries is on the up. Bioquell also owns TRaC, a testing and regulatory services firm that enjoyed a 8% hike in sales to £6.6m. It recently launched a new division branded as Early Stage Qualification (ESQ), this is to provide clients with advice on how best to design their products to comply with regulation. House broker Investec predicts full-year pre-tax profits of £5.2m and EPS of 8.1p. Chief executive Nick Adams quips that Bioquell plans 'global domination' - an ambitious aim but its technology is certainly gaining traction. With net cash of £4.6m, and peers to TRaC selling for up to twice annual revenues Bioquell has an attractive niche and looks undervalued. Long-term buy.
Commenting on the 2011 interim results, Nigel Keen, Chairman of Bioquell PLC, said: "The Group performed well in the first half achieving improved levels of orders, revenues and profitability." "We see interesting opportunities for growth - across our core Life Sciences, Healthcare and Defence sectors - in Asia and other developing markets." "We continue to invest in the expansion of our international sales networks, the development of our product range and TRaC's facilities." "The Group continues to be conservatively financed with significant net cash resources and is well positioned to fund substantial levels of organic growth."
Bioquell PLC - 2011 interim results Bioquell PLC (LSE: BQE) - Bioquell PLC (LSE: BQE) - provider of patented, low temperature, environmentally-friendly bio-decontamination technologies to the Healthcare, Life Sciences and Defence sectors; as well as specialist testing and compliance services in the UK via TRaC - announces its interim results for the six months period ended 30 June, 2011. Group financial highlights: § 14% increase in orders in the period to £23.9 million (2010: £21.0 million) § 11% increase in revenues to £20.0 million (2010: £18.0 million) § Substantial (4x) increase in pre-tax profit to £2.0 million (2010: £0.5 million) § Basic earnings per share of 3.5p (2010: 1.0p) § Significant net cash position combined with a strong balance sheet: net cash of £4.6 million (2010: £3.4 million) and net assets of £25.3 million (2010: £22.6 million) Bio-decontamination (Healthcare, Life Sciences, Defence) division: § Orders increased by 17% to £16.7 million (2010: £14.3 million) § Revenues increased by 13% to £13.4 million (2010: £11.9 million) § Seeing good opportunities for further international, organic growth across all three sectors - assisted by the continuing development of new products TRaC (Testing, Regulatory and Compliance) division: § Orders increased by 7% to £7.2 million (2010: £6.7 million) § Revenues increased by 8% to £6.6 million (2010: £6.1 million) § Plans for further expansion of TRaC in the UK - in part driven by its new consulting business (ESQ)
http://www.investegate.co.uk/Article.aspx?id=201108310700112676N
Yes, had a small dabble last week
29 June, 2011 BIOQUELL PLC Award of a £4 million contract by DEFTECH of Malaysia for the supply of specialist chemical, biological, radiological and nuclear ("CBRN") filtration systems for military vehicles Bioquell PLC (LSE: BQE) ("Bioquell") - provider of specialist low temperature, residue-free bio-decontamination and filtration technologies to the healthcare, life sciences and defence sectors - announces that DRB-HICOM Defence Technologies Sdn Bhd ("DEFTECH"), a substantial Malaysian defence corporation, has awarded Bioquell a contract worth approximately £4 million for the supply of specialist CBRN filtration systems for incorporation into military vehicles being manufactured by DEFTECH in Malaysia. Bioquell will start to supply these CBRN systems at the beginning of 2013 and the contract is scheduled to run for five years. Commenting on this Malaysian contract award, Nick Adams, Group Chief Executive of Bioquell PLC, said: "We are extremely pleased to have been awarded this £4 million CBRN filtration systems contract from a leading Malaysian defence group." "This contract award - which helps build our defence order book - underscores Bioquell's increasing success in the Asia Pacific region."
http://www.hemscott.com/news/static/rna/item.do?newsId=148618753354056
BQE was bought late on Friday afternoon by the Naked Trader - hopefully his followers will now pile in after him: http://www.nakedtrader.co.uk/index.htm "I've made a very speculative buy of Bioquel (BQE) - which provides bug eradication for hospitals and for the military - speculative because I don't normally buy companies that have recently reported reduced profits and have turned down. However I'm taking a chance with an interim statement due any day. Of course the risk is things are still bad and I could lose 20%. However I'm buying as a recovery play because they recently reported orders were on the way up again, they have a decent cash balance and assets so they won't go bust on me. It recently won a decent order from the Middle East and directors in September bought some decent amounts at around the current price. If the statement shows some improvements are coming there could be a nice rise. However of course there's plenty of risk in case things are sliding again. I guess I'm in for a small amount for entertainment. I got 3,000 at 104. Target 150 stop 90. "
7 percent drop so far today!
agm 17-5 10 final ex dividend date 2-6 10 gl all